Publicacions en què col·labora amb MARÍA DE LAS MERCEDES MARÍN ARRIAZA (31)

2023

  1. A mutation responsible for impaired detection by the Xpert SARS-CoV-2 assay independently emerged in different lineages during the SARS-CoV-2 pandemic

    BMC Microbiology, Vol. 23, Núm. 1

  2. Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non–C. difficile diarrhea, and C. difficile–colonized patients

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  3. Microbiome profile and calprotectin levels as markers of risk of recurrent Clostridioides difficile infection

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  4. Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection

    Open Forum Infectious Diseases, Vol. 10, Núm. 2

2022

  1. Clostridioides difficile infection epidemiology and clinical characteristics in COVID-19 pandemic

    Frontiers in Medicine, Vol. 9

  2. Nosocomial Transmission of SARS-CoV-2 Involving Vaccinated Health Care Workers

    Microbiology Spectrum, Vol. 10, Núm. 1

2021

  1. Inference of active viral replication in cases with sustained positive reverse transcription-PCR results for SARS-CoV-2

    Journal of Clinical Microbiology, Vol. 59, Núm. 2

  2. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

    Mycoses, Vol. 64, Núm. 2, pp. 132-143

2020

  1. Clinical impact of a Clostridioides (Clostridium) difficile bedside infectious disease stewardship intervention

    JAC-Antimicrobial Resistance, Vol. 2, Núm. 3

  2. Clostridioides difficile contamination in a clinical microbiology laboratory?

    Clinical Microbiology and Infection, Vol. 26, Núm. 3, pp. 340-344

  3. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules

    Journal of Hospital Infection, Vol. 105, Núm. 2, pp. 319-324

  4. Prediction of poor outcome in Clostridioides difficile infection: A multicentre external validation of the toxin B amplification cycle

    Anaerobe, Vol. 61

  5. Role of Clostridioides difficile in hospital environment and healthcare workers

    Anaerobe, Vol. 63

  6. Three different patterns of positive Clostridium difficile laboratory tests. A comparison of clinical behavior

    Diagnostic Microbiology and Infectious Disease, Vol. 97, Núm. 3

2018

  1. Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin

    Clinical Infectious Diseases

2017

  1. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 10, pp. 1777-1786

  2. C. difficile PCR-ribotype 023 might go undetected when using ChromId C. difficile agar

    Anaerobe, Vol. 44, pp. 34-35

  3. Clinical, immunological and microbiological predictors of poor outcome in Clostridium difficile infection

    Diagnostic Microbiology and Infectious Disease, Vol. 88, Núm. 4, pp. 330-334

  4. Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients

    Anaerobe, Vol. 48, pp. 269-272

2016

  1. Clinical significance of direct cytotoxicity and toxigenic culture in Clostridium difficile infection

    Anaerobe, Vol. 37, pp. 38-42